Comprehensive review by prof. Karim Vermaelen 'Perspectives on the integration of immuno-oncology biomarkers and drugs in a health care setting'

CRIG group leader prof. Karim Vermaelen authored a comprehensive review on 'Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting'.

Immunotherapies are becoming an important component in cancer care but are often associated with challenges such as rather low response rates to these drugs and their high cost with a significant economic impact on the health care system. Implementing a “personalized immuno-oncology” approach can be of use. In this review, the legal framework for the development of valuable in vitro diagnostics is discussed. The clinical validity and utility requirements of predictive immuno-oncology biomarkers is highlighted and an overview is given on the evolution towards multiplex or omics-based assays together with its challenges and pitfalls. Finally, some initiatives between the public and private sector are pinpointed to sustain the future access to innovative medicines in cancer therapy at a reasonable cost.

Link to the full article published in Seminars in Cancer Biology.